No Data
No Data
Cyclacel Pharmaceuticals Shifts Focus to Cancer Drug Development
10-K: FY2024 Annual Report
Cyclacel Pharmaceuticals Appoints New Directors Amid Strategic Shift
8-K: Cyclacel Pharmaceuticals Reports FOURTH quarter financial results and provides business update
Cyclacel Estimates Available Cash, Including Equity Financing, Will Fund Planned Activities Into 2Q >CYCC
Cyclacel Anticipates Significant Decrease to Research and Development Expenses for Yr